Table 2.
Statistics (P value) b |
||||||
---|---|---|---|---|---|---|
Baseline c | 3 Months c | 9 Months c | 3 Mos. vs baseline | 9 Mos. vs baseline | 9 Vs 3 months | |
Study group | ||||||
TSH, mU/L | 5.19 ± 0.61 [5.12] | 3.12 ± 1.01; −40% [2.99; −42%] | 2.01 ± 0.57; −61% [1.92; −62%] | 3.1 × 10−6 | 5.6 × 10−6 | 2.0 × 10−6 |
FT4, pmol/L | 9.63 ± 1.58 [9.17] | 10.67 ± 1.31; +11% [10.53; +15%] | 11.83 ± 1.50; +23% [11.54; +26%] | 0.0073 | 1.8 × 10−6 | 0.71 |
FT3, pmol/L | 5.29 ± 0.61 [5.22] | 4.38 ± 0.47; −17% [4.37; −16%] | 4.32 ± 0.59; −18% [4.33; −17%] | 4.2 × 10−6 | 3.0 × 10−5 | 0.62 |
FT4:FT3 ratio | 1.83 ± 0.32 [1.80] | 2.47 ± 0.46; +35% [2.39; +33%] | 2.78 ± 0.63; +52% [2.69; +49%] | 7.1 × 10−6 | 5.5 × 10−6 | 0.035 |
TPOAb, U/ml | 1020 ± 202 [1021] | 825 ± 183; −19% [777; −24%] | 347 ± 140; −58% [345; −56%] | 0.00034 | 1.7 × 10−6 | 1.8 × 10−6 |
Control group | ||||||
TSH, mU/L | 5.44 ± 0.86 [5.40] (P = 0.31) | 5.43 ± 0.78 [5.60] (P = 1.5 × 10−6) | 5.80 ± 1.18 [5.84] (P = 6.4 × 10−8) | 0.92 | 0.35 | 0.23 |
FT4, pmol/L | 9.58 ± 1.48 [9.04] (P = 0.92) | 9.65 ± 1.46 [9.03] (P = 0.022) | 9.39 ± 1.59 [8.78] (P = 8.6 × 10−6) | 0.89 | 0.73 | 0.64 |
FT3, pmol/L | 5.31 ± 0.75 [5.25] (P = 0.86) | 5.26 ± 0.71 [5.28] (P = 1.1 × 10−5) | 5.37 ± 0.67 [5.31] (P = 2.8 × 10−6) | 0.82 | 0.85 | 0.66 |
FT4:FT3 ratio | 1.81 ± 0.26 [1.78] (P = 0.83) | 1.85 ± 0.30 [1.70] (P = 2.4 × 10−5) | 1.75 ± 0.32 [1.69] (P = 5.8 × 10−7) | 0.70 | 0.39 | 0.59 |
TPOAb, U/ml | 939 ± 140 [930] (P = 0.19) | 914 ± 135 [902] (P = 0.026) | 977 ± 178 [962] (P = 5.8 × 10−7) | 0.79 | 0.58 | 0.33 |
Individual changes are illustrated in Fig. 1.
Difference between means analyzed by ANOVA or Wilcoxon signed rank test for the nongaussian distributed indices (TSH and TPOAb). Statistically significant differences are typed bold-face.
Values in brackets are medians. P values in parentheses refer to the comparison with the study group. Statistically significant differences are typed bold-face.